Medtronic’s new product namely myPTM a smartphone- app that power controls SyncroMed II designed to pump medication into pain patients’ bodies via intrathecal space having been implanted under the skin of pain patients has been granted approval by the FDA. Apart from the daily dosage of the drug, the physician can set limit to the amount of drug that can be administered in a given amount of time. The app is installed in Samsung J3 smartphone and it can wirelessly interface with the SynchroMed II pump to trigger pre- set drug dose blousing.
The app saves a track of drug deliveries that can be viewed by the patient’s physician. On reaching the daily specified limit, the patient will be unable to pump more medicine until the next day.
Vice President and General Manager of the Targeted drug Delivery business, part of the Restorative Therapies Group at Medtronic, Charlie Covert said that the aim is to make targeted drug delivery therapy simple to use and accessible. He further added that the Control Workflow and Clinician Programmer provide physicians with tools to administer the therapy effectively and the app allows the patients customized pain relief. Amid the opioid crisis, Medtronic’s Mission to innovate and expand access, to care for patients is inspiring, as they make sure their efforts benefit patients through their therapies which can help get rid of oral opioids.
According to a recent study a success rate of patients moving from systemic opioids to a targeted drug delivery system is 84%. Medtronic believes that their technology might help address the opioid dependence of many patients.